Skip to main content

PharmaEssentia to Present at the 41st Annual J.P. Morgan Healthcare Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.

A link to the live audio webcast of the presentation will be available on the News page of the PharmaEssentia USA website at us.pharmaessentia.com. An audio replay will be available for 30 days following the presentation.

About PharmaEssentia

PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  261.12
+0.00 (0.00%)
AAPL  267.61
+0.00 (0.00%)
AMD  334.63
+0.00 (0.00%)
BAC  52.63
+0.00 (0.00%)
GOOG  348.52
+0.00 (0.00%)
META  678.62
+0.00 (0.00%)
MSFT  424.82
+0.00 (0.00%)
NVDA  216.61
+0.00 (0.00%)
ORCL  172.96
+0.00 (0.00%)
TSLA  378.67
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.